نتایج جستجو برای: tpa therapy
تعداد نتایج: 659243 فیلتر نتایج به سال:
در این پایاننامه مشتقات تتراهیدروبنزو[b]پیران در حضور کاتالیستهای اسیدی جامد بر پایه tpa/al-mcm-41 از تراکم مالونونیتریل، آلدهید و دایمدون، همچنین مشتقات زانتندایاون از تراکم دای مدون و آلدهید به نسبت 2 به 1 از دو واکنشگر سنتز شدهاند. کاتالیستهای 12–تنگستو فسفریک اسید نشانده شده بر روی al-mcm-41 (tpa/al-mcm-41) با مقادیر مختلف بارگذاری tpa و نسبتهای مولی مختلف si/al سنتز و مشخصات آن...
OBJECTIVE Pulseless electrical activity (PEA) during cardiac arrest portends a poor prognosis. There is a paucity of data in the use of thrombolytic therapy in PEA and cardiopulmonary arrest due to confirmed pulmonary embolism (PE). We evaluated the outcome of low-dose systemic thrombolysis with tissue plasminogen activator (tPA) in patients presenting with PEA due to PE. METHODS During a 34-...
HYPOTHESIS Thrombolytic therapy will decrease the incidence of amputation when administered within 24 hours of exposure. DESIGN Single institution retrospective review of clinical outcomes and resource use. SETTING Burn unit of a tertiary academic referral center. PATIENTS From 2001 to 2006, patients with severe frostbite admitted within 48 hours of injury underwent digital angiography an...
BACKGROUND AND PURPOSE Several studies are currently evaluating tissue-type plasminogen activator (TPA) as a potential therapy in acute ischemic stroke. The possibility of inducing intracranial hematomas, however, introduces an important concern into ultimate evaluation of risk and benefit. This retrospective analysis sought to identify factors associated with intracranial hematoma formation in...
BACKGROUND AND PURPOSE In previous studies, the Totaled Health Risks in Vascular Events (THRIVE) score has shown broad utility, allowing prediction of clinical outcome, death, and risk of hemorrhage after tissue-type plasminogen activator (tPA) treatment, irrespective of the type of acute stroke therapy applied to the patient. METHODS We used data from the Virtual International Stroke Trials ...
The presence of a salvageable penumbra, a region of ischemic brain tissue with sufficient energy for short-term survival, has been widely agreed as the premise for thrombolytic therapy with tissue plasminogen activator (tPA), which remains the only United States Food and Drug Administration (FDA) approved treatment for acute ischemia stroke. However, the use of tPA has been profoundly constrain...
Background: Thrombolytic therapy is the recommended treatment of acute ischemic stroke. It crucial to evaluate results with recombinant Tissue Plasminogen Activator (r-TPA) in patients Objectives: This study aimed outcomes r-TPA stroke a referral center Iran. Materials & Methods: In this retrospective study, 87 symptoms were examined. They referred Gilan Province, Iran, from June 2016 April...
OBJECTIVES To describe the experience of a community teaching hospital emergency department (ED) Code Stroke Protocol (CSP) for identifying acute ischemic stroke (AIS) patients and treating them with tissue plasminogen activator (tPA) and to compare outcome measures with those achieved in the National Institute of Neurological Disorders and Stroke (NINDS) trial. METHODS This study was a retro...
BACKGROUND AND PURPOSE The goal of this study is to combine temporary endovascular bypass (TEB) with a novel shear-activated nanotherapeutic (SA-NT) that releases recombinant tissue-type plasminogen activator (r-tPA) when exposed to high levels of hemodynamic stress and to determine if this approach can be used to concentrate r-tPA at occlusion sites based on high shear stresses created by sten...
نمودار تعداد نتایج جستجو در هر سال
با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید